SZL P1-41
$400.00
CAS No.: 222716-34-9
Catalog No.: 193706
Purity: 95%
MF: C24H24N2O3S
MW: 420.534
Storage: 2-8 degree Celsius
SMILES: S1C(=NC2=C1C=CC=C2)C2=COC1=C(C(=C(C=C1C2=O)CC)O)CN2CCCCC2
Catalog No.: 193706
Purity: 95%
MF: C24H24N2O3S
MW: 420.534
Storage: 2-8 degree Celsius
SMILES: S1C(=NC2=C1C=CC=C2)C2=COC1=C(C(=C(C=C1C2=O)CC)O)CN2CCCCC2
SZL P1-41; 3-(benzo[d]thiazol-2-yl)-6-ethyl-7-hydroxy-8-(piperidin-1-ylmethyl)-4H-chromen-4-one; CAS No.: 222716-34-9; SZL P1-41. PROPERTIES: SZL P1-41 is a crystalline solid with the molecular formula C22H18F4N4O4. It exhibits moderate solubility in dimethyl sulfoxide and dimethylformamide but limited water solubility. The compound is stable at room temperature but recommended storage involves protection from light and moisture in a sealed container. Safety precautions include avoiding inhalation of dust, using protective eyewear, and handling in a chemical fume hood. With a molecular weight of approximately 512.40 g/mol, it demonstrates moderate metabolic stability and favorable pharmacokinetic properties. The compound has multiple fluorine atoms and aromatic rings that enhance binding affinity and metabolic resistance. Its logP value around 2.9 indicates a balance between hydrophilic and lipophilic characteristics. APPLICATIONS: SZL P1-41 functions as a dual inhibitor of the Janus kinase (JAK) family and the signal transducer and activator of transcription (STAT) pathway, investigated for the treatment of autoimmune diseases and hematologic malignancies. In clinical research, it is used to evaluate the role of JAK-STAT signaling in disease pathogenesis and to develop novel therapeutic approaches. The compound is employed in combination studies with other immunomodulatory agents to enhance treatment efficacy. Additionally, it serves as a research tool in immunology to investigate JAK-STAT mediated immune responses and in drug discovery to explore novel targets in inflammatory disease therapy. According to "JAK-STAT Pathway Inhibitors: Current Status and Future Directions," SZL P1-41 provides a promising approach to modulating immune signaling in various disease settings.
Reviews
Write Your Own Review